Bullish
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has received an average rating of "Moderate Buy" from eleven brokerages, with an average one-year price t...
Bearish
Wall Street Zen has upgraded Corbus Pharmaceuticals (NASDAQ:CRBP) from a "strong sell" to a "sell" rating. Despite this, MarketBeat maintains an avera...
Neutral
Corbus Pharmaceuticals recently updated the employment agreements for CEO Yuval Cohen and CFO Sean Moran, extending their terms until April 2028. Thes...